Compare Quest Diagnostics Inc (DGX) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Icl Group Ltd — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Icl Group Ltd trades at $5.02 (market cap $6.47B). The key difference: Quest Diagnostics Inc is far larger — about 3.9× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Icl Group Ltd for 56 Days on average.
| DGX | ICL | |
|---|---|---|
Market Cap | $25.48B | $6.47B |
Volume | 941,866 | 1,387,140 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $6.84 |
52-Week Low | $173.49 | $4.80 |
Typical Hold Time | 56 Days | 56 Days |
Enterprise Value | $31.23B | $9.11B |
Dividend Yield | 1.49% | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
ICL trades at $5.00, down 1.57% on the day. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 earnings of $0.12 per share, beating estimates, but revenue and net income margins have declined from prior years. Valuation ratios like P/E of 20.83 and P/S of 0.84 suggest moderate pricing relative to earnings and sales. A dividend of $0.06 is scheduled for payment in September 2026.
The outlook is mixed. Positive earnings beats and a low EV/EBITDA of 6.68 indicate potential value, but bearish technicals and declining profitability pose risks. Analyst consensus is neutral with a $6.08 price target, implying upside. Key risks include industry headwinds like higher input costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
